Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Benzimidazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | WNT3A | P56704 | 1/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.41 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzimidazole SCHEMBL990184 | 1.00 | ALOX12 (0.46) | ALOX12SMN1; SMN2KDM4EALDH1A1HPGD | |
| Benzimidazole SCHEMBL29439119 | 0.92 | SMN1; SMN2 (0.47) | ALOX12SMN1; SMN2KDM4EALDH1A1HPGD | |
| Benzimidazole SCHEMBL11103584 | 0.92 | SMN1; SMN2 (0.47) | ALOX12SMN1; SMN2KDM4EALDH1A1HPGD | |
| Benzimidazole SCHEMBL11103578 | 0.92 | SMN1; SMN2 (0.47) | ALOX12SMN1; SMN2KDM4EALDH1A1HPGD | |
| Benzimidazole SCHEMBL11103574 | 0.92 | SMN1; SMN2 (0.47) | ALOX12SMN1; SMN2KDM4EALDH1A1HPGD | |
| Benzimidazole SCHEMBL28802233 | 0.92 | SMN1; SMN2 (0.47) | ALOX12SMN1; SMN2KDM4EALDH1A1HPGD | |
| Benzimidazole SCHEMBL19876247 | 0.92 | SMN1; SMN2 (0.46) | ALOX12SMN1; SMN2KDM4EALDH1A1HPGD | |
| Benzimidazole SCHEMBL1128586 | 0.89 | ALOX5AP (0.44) | ALOX12SMN1; SMN2KDM4EALDH1A1HPGD | |
| Benzimidazole SCHEMBL15092689 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EALDH1A1HPGDHTT | |
| Benzimidazole SCHEMBL28361412 | 0.89 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4EALDH1A1HPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4560746-A1 | METHOD FOR DOPING OF DENSE FILMS AND POROUS MEMBRANES BASED ON POLYBENZIMIDAZOLES WITH PROTON CONDUCTIVE ELECTROLYTOS BASED ON CONCENTRATED BRONSTED ACID/BENZIMIDAZOLE MIXTURES | Institute of Polymers Bulgarian Academy of Sciences (BG) | 2025-05-28 | — | — | EP | disclosed |
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| CN-100377406-C | Electrolyte material for fuel cell | TOYOTA MOTOR CO LTD (JP) | 2008-03-26 | — | — | CN | disclosed |
| US-7320995-B2 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | ELI LILLY AND COMPANY (US) | 2008-01-22 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| CN-1788380-A | Electrolyte material for fuel cell | TOYOTA MOTOR CO LTD (JP) | 2006-06-14 | — | — | CN | disclosed |
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | EIL LILLY AND COMPANY (US) | 2005-12-08 | — | — | US | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272791-A1 | Benzimidazoles and benzothiazoles as inhibitors of map kinase | MAP3K8, MAPK8, MAPK1 | ALOX12 4666/4885SMN1; SMN2 4631/4885KDM4E 2781/4885 |
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | ALOX12 4697/4885SMN1; SMN2 3611/4885KDM4E 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.